



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2020-N-0001, FDA-2020-N-0255, FDA-2020-N-0256, FDA-2020-N-0259, FDA-2018-N-4337]

March 10 Through April 30, 2020, Public Meetings; Postponement, Cancellation, or Remote Only

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration is announcing that certain meetings involving the Center for Drug Evaluation and Research (CDER) from March 10 through April 30, 2020, are postponed, cancelled, or modified to take place remotely.

DATES: For dates that have been either postponed or cancelled, see table 1 in the

SUPPLEMENTARY INFORMATION section.

FOR FURTHER INFORMATION CONTACT: Kim Thomas, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6282, Silver Spring, MD 20993-0002, 301-796-2357, Kimberly.K.Thomas@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Certain public meetings involving CDER from March 10 through April 30, 2020, are postponed, cancelled, or modified to take place remotely due to extenuating circumstances. The meetings that are postponed or canceled as part of this notice are listed in table 1. If a meeting is rescheduled, information about the rescheduled meeting will be

provided in the future. The meeting that will no longer take place in person and instead take place by webcast only as part of this notice is listed in table 2.¹

Table 1.--CDER Meetings Postponed or Cancelled

Meeting Type	Meeting Title	Original Meeting Date	Docket No.	<i>Federal Register</i> Citation
Public Meeting	Patient-Focused Drug Development for Stimulant Use Disorder	Mar. 10, 2020	FDA-2020-N-0259	85 FR 8877, Feb. 18, 2020
Public Meeting	Patient-Focused Drug Development for Vitiligo	Mar. 30, 2020	FDA-2020-N-0255	85 FR 8004, Feb. 12, 2020
Public Meeting	Scientific and Ethical Considerations for the Inclusion of Pregnant Women in Clinical Trials	Apr. 16, 2020	FDA-2020-N-0001	85 FR 14207, Mar. 11, 2020
Public Meeting	Prescription Drug User Fee Act of 2017; Electronic Submissions and Data Standards	Apr. 22, 2020	FDA-2018-N-4337	85 FR 6547, Feb. 5, 2020

Table 2.--CDER Meeting Held Remotely

Meeting Type	Meeting Title	Original Meeting Date	Docket No.	<i>Federal Register</i> Citation	Remote Information
Public Meeting	United States Food and Drug Administration and Health Canada Joint Regional Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use	Apr. 3, 2020	FDA-2020-N-0256	85 FR 13659, Mar. 9, 2020	https://www.fda.gov/drugs/news-events-human-drugs/health-canada-and-fda-joint-public-consultation-international-council-harmonisation-technical-0

¹ Up-to-date information about public meetings involving CDER is available on the internet at <https://www.fda.gov/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs>.

Dated: March 16, 2020.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.

[FR Doc. 2020-05743 Filed: 3/18/2020 8:45 am; Publication Date: 3/19/2020]